Opioid Tolerance, Dependence, and Hyperalgesia

Opioid-Induced Hyperalgesia

Volumn , Issue , 2016, Pages 61-73

  Ballantyne, Jane C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85135426046     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420089004-8     Document Type: Chapter

References (73)

1. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction 2001; 96: 103-114.
2. Robinson TE, Berridge KC. Addiction. Annu Rev Psychol 2003; 54: 25-53.
3. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278: 52-58.
4. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24: 97-129.
5. Gardner EL. The neurobiology and genetics of addiction: implications of the reward deficiency syndrome for therapeutic strategies in chemical dependency. In: Elster J, ed. Addiction: Entries and Exits. New York: Russell Sage Foundation, 1999: 57-119.
6. Gardner EL. Brain-reward mechanisms. In: Lowinson JH, Ruiz P, Milman RB, et al., eds. Substance Abuse: A Comprehensive Textbook. Philadelphia: Lippincott Williams and Wilkins, 2005: 48-97.
7. Mitchell JM, Basbaum AI, Fields HL. A locus and mechanism of action for associative morphine tolerance. Nat Neurosci 2000; 3: 47-53.
8. Grisel JE, Watkins LR, Maier SF. Associative and non-associative mechanisms of morphine analgesic tolerance are neurochemically distinct in the rat spinal cord. Psychopharmacology (Berlin) 1996; 128: 248-255.
9. Bohn LM, Gainetdinov RR, Lin FT, et al. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000; 408: 720-723.
10. Taylor DA, Fleming WW. Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. J Pharmacol Exp Ther 2001; 297: 11-18.
11. Watts VJ. Molecular mechanisms for heterologous sensitization of adenylate cyclase. J Pharmacol Exp Ther 2002; 302: 1-7.
12. He L, Whistler JL. An opiate cocktail that reduces morphine tolerance and dependence. Curr Biol 2005; 15: 1028-1033.
13. Trujillo KA. Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies. Psychopharmacology (Berlin) 2000; 151: 121-141.
14. Nitsche JF, Schuller AG, King MA, et al. Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci 2002; 22: 10906-10913.
15. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene [see comment]. Science 2003; 301: 386-389.
16. Raith K, Hochhaus G. Drugs used in the treatment of opioid tolerance and physical dependence: a review. Int J Clin Pharmacol Ther 2004; 42: 191-203.
17. Lim G, Wang S, Zeng Q, et al. Spinal glucocorticoid receptors contribute to the development of morphine tolerance in rats. Anesthesiology 2005; 102: 832-837.
18. Lim G, Wang S, Zeng Q, et al. Evidence for a long-term influence on morphine tolerance after previous morphine exposure: role of neuronal glucocorticoid receptors. Pain 2005; 114: 81-92.
19. Lim G, Wang S, Zeng Q, et al. Expression of spinal NMDA receptor and PKCgamma after chronic morphine is regulated by spinal glucocorticoid receptor. J Neurosci 2005; 25: 11145-11154.
20. Zhao M, Joo DT. Enhancement of spinal N-methyl-D-aspartate receptor function by remifentanil action at delta-opioid receptors as a mechanism for acute opioidinduced hyperalgesia or tolerance. Anesthesiology 2008; 109: 308-317.
21. Nestler EJ. Molecular mechanisms of drug addiction. Neuropharmacology 2004; 47(suppl. 1): 24-32.
22. Vanderah TW, Gardell LR, Burgess SE, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000; 20: 7074-7079.
23. Vanderah TW, Ossipov MH, Lai J, et al. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain 2001; 92: 5-9.
24. Carlezon W, Duman R, Nestler EJ. The many faces of CREB. Trends Neurosci 2005; 28: 436-445.
25. Cesselin F. Opioid and anti-opioid peptides. Fundam Clin Pharmacol 1995; 9: 409-433.
26. Wiesenfeld-Hallin Z, Xu XJ. Neuropeptides in neuropathic and inflammatory pain with special emphasis on cholecystokinin and galanin. Eur J Pharmacol 2001; 429: 49-59.
27. Xu XJ, Colpaert F, Wiesenfeld-Hallin Z. Opioid hyperalgesia and tolerance versus 5-HT1A receptor-mediated inverse tolerance. Trends Pharmacol Sci 2003; 24: 634-639.
28. Koob GF, Maldonado R, Stinus L. Neural substrates of opiate withdrawal. Trends Neurosci 1992; 15: 186-191.
29. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997; 278: 58-63.
30. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006; 29: 565-598.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
32. Bruera E, Brenneis C, Michaud M, et al. Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 1988; 62: 407-411.
33. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006; 32: 304-315.
34. de Leon-Casasola OA, Myers DP, Donaparthi S, et al. A comparison of postoperative epidural analgesia between patients with chronic cancer taking high doses of oral opioids versus opioid-naive patients. Anesth Analg 1993; 76: 302-307.
35. Rapp SE, Ready LB, Nessly ML. Acute pain management in patients with prior opioid consumption: a case-controlled retrospective review. Pain 1995; 61: 195-201.
36. Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. Anesthesiology 2004; 101: 212-227.
37. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006; 104: 570-587.
38. Wilder-Smith OH, Arendt-Nielsen L. Postoperative hyperalgesia: its clinical importance and relevance. Anesthesiology 2006; 104: 601-607.
39. Yu W, Hao JX, Xu XJ, et al. The development of morphine tolerance and dependence in rats with chronic pain. Brain Res 1997; 756: 141-146.
40. South SM, Smith MT. Analgesic tolerance to opioids. Pain Clin Updates IASP Press 2001; 9: 1-4.
41. Bailey CP, Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 2005; 5: 60-68.
42. McQuay H. Opioids in pain management. Lancet 1999; 353: 2229-2232.
43. von Zastrow M. A cell biologist’s perspective on physiological adaptation to opiate drugs. Neuropharmacology 2004; 47(suppl. 1): 286-292.
44. Hyman SE. Dispelling the myths about addiction. Washington: Institute of Medicine National Academy of Sciences Press, 1997: 44-46.
45. Cami J, Farre M. Drug addiction. N Engl J Med 2003; 349: 975-986.
46. Compton P, Athanasos P, Elashoff D. Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. J Pain 2003; 4: 511-519.
47. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006; 144: 127-134.
48. Compton P, Darakjian JM, Miotto K. Screening for addiction in patients with chronic pain with “problematic” substance use: evaluation of a pilot assessment tool. J Pain Symptom Manage 1998; 16: 355-363.
49. Brodner RA, Taub A. Chronic pain exacerbated by long-term narcotic use in patients with non-malignant disease: clinical syndrome and treatment. Mt Sinai J Med 1978; 45: 233-237.
50. Taylor CB, Zlutnick SI, Corley MJ, et al. The effects of detoxification, relaxation and brief supportive therapy on chronic pain. Pain 1980; 8: 319-329.
51. Savage SR. Long-term opioid therapy: assessment of consequences and risks. J Pain Symptom Manage 1996; 11: 274-286.
52. Compton MA. Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. J Pain Symptom Manage 1994; 9: 462-473.
53. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006; 7: 43-48.
54. Devulder J. Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol 1997; 9: 146-148.
55. Vorobeychik Y, Chen L, Bush MC, et al. Improved opioid analgesic effect following opioid dose reduction. Pain Med 2008; 9: 724-727.
56. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008; 24: 479-496.
57. Doverty M, White JM, Somogyi AA, et al. Hyperalgesic responses in methadone maintenance patients [see comment]. Pain 2001; 90: 91-96.
58. Jamison RN, Kauffman J, Katz NP. Characteristics of methadone maintenance patients with chronic pain. J Pain Sympt Manage 2000; 19: 53-62.
59. Rosenblum A, Joseph H, Fong C, et al. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003; 289: 2370-2378.
60. Angst MS, Koppert W, Pahl I, et al. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 2003; 106: 49-57.
61. Hood DD, Curry R, Eisenach JC. Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia. Anesth Analg 2003; 97: 810-815.
62. Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000; 93: 409-417.
63. Fields H. State-dependent opioid control of pain. Nat Rev Neurosci 2004; 5: 565-575.
64. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003; 349: 1943-1953.
65. Fishbain D, Cutler R, Rosomoff HL, et al. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain 1997; 113: 116-137.
66. Dersh J, Polatin PB, Gatchell RJ. Chronic pain and psychopathology: research finding and theoretical considerations. Psychosom Med 2002; 64: 773-786.
67. McWilliams L, Goodwin R, Cox B. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain 2004; 111: 77-83.
68. Wasan AD, Davar G, Jamison R. The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain 2005; 117: 450-461.
69. Sullivan MD, Edlund MJ, Zhang L, et al. Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med 2006; 166: 2087-2093.
70. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: WHO, 1992.
71. WHO Expert Committee on Drug Dependence. 30th report. Geneva, Switzerland: WHO, 1998.
72. Heit HA. Addiction, physical dependence, and tolerance: precise definitions to help clinicians evaluate and treat chronic pain patients (review). J Pain Palliat Care Pharmacother 2003; 17: 15-29.
73. Ballantyne JC, LaForge SL. Opioid dependence and addiction in opioid-treated pain patients. Pain 2007; 129: 235-255.